Overview

Efficacy and Safety of ACH24 in the Treatment of Vitiligo

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter clinical trial, phase III, randomized, placebo-controlled, parallel group, enroll 94 patients, to assess the efficacy of ACH24 in the repigmentation of achromatic areas in patients with vitiligo.
Phase:
Phase 3
Details
Lead Sponsor:
Ache Laboratorios Farmaceuticos S.A.